-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Measurable Residual Disease Smith Giri, MD, MHS 1 *, Binod Dhakal, MBBS 2, Natalie Callander, MD 3, Eva Medvedova, MD 4 *, Kelly Godby 1 *, Susan Bal, MD 1, Gayathri Ravi, MD 1, Saurabh Chhabra, MD 5,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Paper: Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma - 7 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and P lasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Adult, Translational Research, Plasma Cell Disorders, Bioinformatics, Diseases, Lymphoid Malignancies, Computational biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease Palak Bajaj 1 *, Ola Landgren 2, Damian J. Green, MD 3 and David G.
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma. Validation in larger prospective studies needed @DrOlaLandgren #mmsm https://t.co/dLcH3w7xhn
-
-
Mashup Score: 0The best books of 2024, as chosen by The Economist - 8 day(s) ago
Readers will never think the same way again about games, horses and spies
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet-
The best books of 2024, as chosen by The Economist https://t.co/PBrJ6WBMJc
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm @ldandersonjr https://t.co/jfvL4Pi0Dj
-
-
Mashup Score: 12Paper: Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis - 9 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Measurable Residual Disease Noemi Puig, PhD 1,2, Cristina Agullo 2 *, Bruno Paiva, PhD 3,4,5,6 *, María T Cedena 7 *, Laura Rosiñol Dachs 8,9,10 *, Teresa Contreras 11 *, Joaquín Martínez-Lopez 12,13 *, Albert Oriol 14,15 *, María-Jesús Blanchard, MD, PhD 16,17 *, Rafael
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Reevaluating the IMWG MM CR Criteria with Mass Spectrometry (MS) -MS surpasses the clinical value of BM PC% and sIFE -Study suggests that BM aspirate is only needed for MRD assessment #mmsm #bmtsm @NoemiPuig2 @mvmateos @BrunoPaiva_UNAV https://t.co/CTUMNyiJtu
-
-
Mashup Score: 55Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation - 11 day(s) ago
Blood Cancer Journal – Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Optimal infused CD34+ cell dose in NDMM patients undergoing upfront autoHCT: >2.5 × 106 cells/kg. Phenomenal work by #orenpasvolsky @MDAndersonNews @marcoux_curtis @BloodCancerJnl #mmsm #bmtsm https://t.co/69nL1MuoAd
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Measurable Residual Disease Smith Giri, MD, MHS 1 *, Binod Dhakal, MBBS 2, Natalie Callander, MD 3, Eva Medvedova, MD 4 *, Kelly Godby 1 *, Susan Bal, MD 1, Gayathri Ravi, MD 1, Saurabh Chhabra, MD 5,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 In the setting of quadruplet induction + autoSCT in NDMM, sustained MRD at 10e-5 is the best predictor of MRD resurgence and progression after fixed duration Rx #bmtsm #mms @smith__giri @End_myeloma https://t.co/BqWf3cv7Wl
-
-
Mashup Score: 0An immigration fix to address the health care workforce crisis - 12 day(s) ago
Former HHS Secretary Tom Price writes that the new Trump administration should update immigration laws to help the U.S. health care workforce crisis.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet-
An immigration fix to address the health care workforce crisis @SecPriceMD https://t.co/J9wJwf0ZDp via @statnews
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Measurable Residual Disease Smith Giri, MD, MHS 1 *, Binod Dhakal, MBBS 2, Natalie Callander, MD 3, Eva Medvedova, MD 4 *, Kelly Godby 1 *, Susan Bal, MD 1, Gayathri Ravi, MD 1, Saurabh Chhabra, MD 5,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 In the setting of quadruplet induction + autoSCT in NDMM, sustained MRD at 10e-5 is the best predictor of MRD resurgence and progression after fixed duration Rx #bmtsm #mms @smith__giri @End_myeloma https://t.co/BqWf3cv7Wl
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm @ldandersonjr https://t.co/jfvL4Pi0Dj
-
#ASH24 In the setting of quadruplet induction + autoSCT in NDMM, sustained MRD at 10e-5 is the best predictor of MRD resurgence and progression after fixed duration Rx #bmtsm #mms @smith__giri @End_myeloma https://t.co/BqWf3cv7Wl